GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R

Diabetes

Volumn 64, Issue 7, 2015, Pages 2537-2549

  Yusta, Bernardo ^a   Baggio, Laurie L ^a   Koehler, Jacqueline ^a   Holland, Dianne ^a   Cao, Xiemin ^a   Pinnell, Lee J ^b   Johnson Henry, Kathene C ^b   Yeung, William ^b   Surette, Michael G ^c   Bang, K W Annie ^a   Sherman, Philip M ^b   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; EXENDIN 4; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; KERATINOCYTE GROWTH FACTOR; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; CYTOKINE; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; INTESTINE CELL; INTESTINE INJURY; INTESTINE INNERVATION; INTESTINE MUCOSA; MALE; MOUSE; NONHUMAN; PATHOGEN CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION CHIMERA; SMALL INTESTINE; SPLEEN CELL; TURNOVER TIME; UPREGULATION; AGONISTS; ANIMAL; C57BL MOUSE; IMMUNOLOGY; LYMPHOCYTE; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; IMMUNITY, INNATE; INTESTINAL MUCOSA; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; PEPTIDES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; VENOMS;

EID: 84962086818     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1577     Document Type: Article

References (52)

1. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
2. Xiao Q, Boushey RP, Cino M, Drucker DJ, Brubaker PL. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 2000;278:R1057-R1063
3. Eissele R, Göke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992;22: 283-291
4. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17:819-837
5. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
6. Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol 2014;76:561-583
7. Nauck MA. Is glucagon-like peptide 1 an incretin hormone? Diabetologia 1999;42:373-379
8. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481-1489
9. Nguyen AT, Mandard S, Dray C, et al. Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: Involvement of the GLP-1 pathway. Diabetes 2014;63:471-482
10. Kahles F, Meyer C, Möllmann J, et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 2014;63:3221-3229
11. Cheroutre H, Lambolez F, Mucida D. The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol 2011;11:445-456
12. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004;53:1326-1335
13. Lefrançois L, Lycke N. Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells. Curr Protoc Immunol 2001; 4:3.19.1-3.19.16
14. Leung FW, Miller JC, Reedy TJ, Guth PH. Exogenous prostaglandin protects against acid-induced deep mucosal injury by stimulating alkaline secretion in rat duodenum. Dig Dis Sci 1989;34:1686-1691
15. Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A 2002;99:14338-14343
16. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013;154:127-139
17. Auletta JJ, Devecchio JL, Ferrara JL, Heinzel FP. Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2004;10:834-847
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162: 156-159
19. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 2010;53:730-740
20. Assa A, Vong L, Pinnell LJ, et al. Vitamin D deficiency predisposes to adherent-invasive Escherichia coli-induced barrier dysfunction and experimental colonic injury. Inflamm Bowel Dis 2015;21:297-306
21. Huson DH, Mitra S, Ruscheweyh HJ, Weber N, Schuster SC. Integrative analysis of environmental sequences using MEGAN4. Genome Res 2011;21: 1552-1560
22. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor-or not? Endocrinology 2013;154:4-8
23. Richards P, Parker HE, Adriaenssens AE, et al. Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model. Diabetes 2014;63:1224-1233
24. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-2978
25. Qiu Y, Yang H. Effects of intraepithelial lymphocyte-derived cytokines on intestinal mucosal barrier function. J Interferon Cytokine Res 2013;33:551-562
26. Kronenberg M, Havran WL. Frontline T cells: Gammadelta T cells and intraepithelial lymphocytes. Immunol Rev 2007;215:5-7
27. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994;134:2156-2164
28. Kedees MH, Guz Y, Grigoryan M, Teitelman G. Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor. Peptides 2013;48:36-44
29. Schmidtler J, Dehne K, Allescher H-D, et al. Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-linking, and radioligand binding. Am J Physiol 1994;267:G423-G432
30. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155:1280-1290
31. Wang H, Steeds J, Motomura Y, et al. CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 2007;56:949-957
32. Selleri S, Palazzo M, Deola S, et al. Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS. Int Immunol 2008;20:961-970
33. Qian BF, Hammarström ML, Danielsson A. Differential expression of vasoactive intestinal polypeptide receptor 1 and 2 mRNA in murine intestinal T lymphocyte subtypes. J Neuroendocrinol 2001;13:818-825
34. Bogunovic M, Davé SH, Tilstra JS, et al. Enteroendocrine cells express functional Toll-like receptors. Am J Physiol Gastrointest Liver Physiol 2007;292: G1770-G1783
35. Jin C, Henao-Mejia J, Flavell RA. Innate immune receptors: Key regulators of metabolic disease progression. Cell Metab 2013;17:873-882
36. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444: 860-867
37. Pais R, Zietek T, Hauner H, Daniel H, Skurk T. RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice. Am J Physiol Gastrointest Liver Physiol 2014;307:G330-G337
38. Rinaman L, Comer J. Antagonism of central glucagon-like peptide-1 receptors enhances lipopolysaccharide-induced fever. Auton Neurosci 2000;85: 98-101
39. Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: Diabetes meets dermatology. Diabetologia 2011;54:2741-2744
40. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001;61:687-693
41. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999;276:G79-G91
42. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999;277:E937-E947
43. Lee S-J, Lee J, Li KK, et al. Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology 2012;153:1141-1151
44. Hadjiyanni I, Li KK, Drucker DJ. Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse. Endocrinology 2009;150:592-599
45. Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 2010;139:857-868
46. Cani PD, Possemiers S, Van De Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-1103
47. Schéle E, Grahnemo L, Anesten F, Hallén A, Bäckhed F, Jansson JO. The gut microbiota reduces leptin sensitivity and the expression of the obesity-suppressing neuropeptides proglucagon (Gcg) and brain-derived neurotrophic factor (Bdnf) in the central nervous system. Endocrinology 2013;154:3643-3651
48. Wichmann A, Allahyar A, Greiner TU, et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe 2013;14: 582-590
49. Chimerel C, Emery E, Summers DK, Keyser U, Gribble FM, Reimann F. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Reports 2014;9:1202-1208
50. Tsalikis J, Croitoru DO, Philpott DJ, Girardin SE. Nutrient sensing and metabolic stress pathways in innate immunity. Cell Microbiol 2013;15:1632-1641
51. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007;117:143-152
52. Hartstra AV, Bouter KE, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 2015;38: 159-165